Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Idec Zevalin

Executive Summary

FDA's Oncologic Drugs Advisory Committee is expected to consider the radioimmunotherapy Zevalin (ibritumomab tiuxetan) for treatment of relapsed or refractory, low grade or follicular non-Hodgkin's lymphoma during the first quarter, Idec CEO William Rastetter, PhD, tells the J.P. Morgan H&Q Healthcare Conference in San Francisco Jan. 11. The next scheduled oncologics committee meeting is in March
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS037186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel